MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
USA - NASDAQ:MDXG - US6024961012 - Common Stock
7.21 USD
+0.5 (+7.45%)
7.01 USD
-0.2 (-2.77%)
We assign a fundamental rating of 5 out of 10 to MDXG. MDXG was compared to 536 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
MDXG has a better Return On Assets (11.05%) than 94.03% of its industry peers.
MDXG has a Return On Equity of 14.85%. This is amongst the best in the industry. MDXG outperforms 94.40% of its industry peers.
MDXG has a better Return On Invested Capital (13.37%) than 95.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROIC | 13.37% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDXG (8.84%) is better than 91.98% of its industry peers.
MDXG has a Operating Margin of 12.07%. This is amongst the best in the industry. MDXG outperforms 92.72% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
The Gross Margin of MDXG (81.45%) is better than 85.45% of its industry peers.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
MDXG has more shares outstanding than it did 1 year ago.
MDXG has more shares outstanding than it did 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 10.69 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG has a Altman-Z score of 10.69. This is amongst the best in the industry. MDXG outperforms 83.96% of its industry peers.
MDXG has a debt to FCF ratio of 0.32. This is a very positive value and a sign of high solvency as it would only need 0.32 years to pay back of all of its debts.
MDXG's Debt to FCF ratio of 0.32 is amongst the best of the industry. MDXG outperforms 95.90% of its industry peers.
MDXG has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
MDXG has a Debt to Equity ratio of 0.08. This is in the lower half of the industry: MDXG underperforms 62.50% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Altman-Z | 10.69 |
ROIC/WACC1.34
WACC10.01%
2.3 Liquidity
A Current Ratio of 4.39 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio (4.39) which is in line with its industry peers.
A Quick Ratio of 3.90 indicates that MDXG has no problem at all paying its short term obligations.
The Quick ratio of MDXG (3.90) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.39%.
The Revenue has been growing slightly by 6.85% in the past year.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
3.2 Future
The Earnings Per Share is expected to grow by 15.23% on average over the next years. This is quite good.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 27.73, the valuation of MDXG can be described as expensive.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 93.28% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.86. MDXG is around the same levels.
Based on the Price/Forward Earnings ratio of 20.59, the valuation of MDXG can be described as rather expensive.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 92.72% of the companies in the same industry.
MDXG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.73 | ||
| Fwd PE | 20.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.59% of the companies listed in the same industry.
95.15% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.58 | ||
| EV/EBITDA | 17.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 15.23% in the coming years.
PEG (NY)1.94
PEG (5Y)N/A
EPS Next 2Y9.89%
EPS Next 3Y15.23%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.21
+0.5 (+7.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change0%
Ins Owners1.83%
Ins Owner Change0.62%
Market Cap1.07B
Analysts81.82
Price Target12.44 (72.54%)
Short Float %3.27%
Short Ratio7.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.25%
Min EPS beat(2)6.95%
Max EPS beat(2)81.55%
EPS beat(4)3
Avg EPS beat(4)17%
Min EPS beat(4)-31.92%
Max EPS beat(4)81.55%
EPS beat(8)7
Avg EPS beat(8)68.99%
EPS beat(12)10
Avg EPS beat(12)59.73%
EPS beat(16)12
Avg EPS beat(16)49.94%
Revenue beat(2)2
Avg Revenue beat(2)3.5%
Min Revenue beat(2)0.32%
Max Revenue beat(2)6.68%
Revenue beat(4)3
Avg Revenue beat(4)2.13%
Min Revenue beat(4)-0.35%
Max Revenue beat(4)6.68%
Revenue beat(8)6
Avg Revenue beat(8)1.52%
Revenue beat(12)8
Avg Revenue beat(12)2.12%
Revenue beat(16)12
Avg Revenue beat(16)2.46%
PT rev (1m)0%
PT rev (3m)1.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.69%
EPS NY rev (1m)0%
EPS NY rev (3m)31.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.73 | ||
| Fwd PE | 20.59 | ||
| P/S | 2.93 | ||
| P/FCF | 18.58 | ||
| P/OCF | 18.35 | ||
| P/B | 4.92 | ||
| P/tB | 5.76 | ||
| EV/EBITDA | 17.75 |
EPS(TTM)0.26
EY3.61%
EPS(NY)0.35
Fwd EY4.86%
FCF(TTM)0.39
FCFY5.38%
OCF(TTM)0.39
OCFY5.45%
SpS2.46
BVpS1.46
TBVpS1.25
PEG (NY)1.94
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROCE | 18.24% | ||
| ROIC | 13.37% | ||
| ROICexc | 26.4% | ||
| ROICexgc | 35.58% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% | ||
| FCFM | 15.78% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 6.78% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | 28.3 | ||
| Cash Conversion | 106.77% | ||
| Profit Quality | 178.44% | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 10.69 |
F-Score5
WACC10.01%
ROIC/WACC1.34
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
EBIT growth 1Y-29.45%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5YN/A
FCF growth 1Y1521.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6349.89%
OCF growth 3YN/A
OCF growth 5YN/A